Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 15/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092718 | 0.92 | NR1H2 (0.41) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1092369 | 0.89 | NR1H2 (0.36) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1092673 | 0.88 | L3MBTL1 (0.42) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1092330 | 0.88 | NR1H2 (0.39) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1092571 | 0.87 | NR1H2 (0.36) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1092106 | 0.86 | NR1H2 (0.36) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1092773 | 0.85 | AR (0.45) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1092807 | 0.84 | MEN1 (0.37) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1253786 | 0.82 | SLC6A4 (0.48) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL1253784 | 0.81 | NR1H2 (0.38) | PPARGPPARDPPARANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153634-B2 | Carbinol derivatives having cyclic linker | KOWA COMPANY, LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2281817-A1 | SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER | Kowa Company, Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | NR1H2, NR1H3, LDLR | PPARG 384/4885PPARD 708/4885PPARA 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.